O015 Il-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses

Abstract

IntroductionSecukinumab (anti-IL-17A) is an effective therapy for ankylosing spondylitis(AS) and psoriatic arthritis (PsA), the prototypical forms of spondyloarthritis (SpA).ObjectivesThis study assessed if secukinumab modulates the immunopathology of target lesions without...